SLCO2A1 in both transporter and channel modes is expected to serve as a perspective pharmacological target for developing new therapeutics for treatment of both inherited and acquired skin, bone, gut, neuronal, and muscular disorders, as well as malignancies involving SLCO2A1. The gene discussed is SLCO2A1; the disease is muscle tissue disorder.